Exelixis (EXEL) Short term Debt (2010 - 2017)
Exelixis (EXEL) recorded quarterly Short term Debt of $113.3 million in Q1 2017, up 3.87% quarter-over-quarter from $109.1 million in Q4 2016, and up 312.18% on a YoY basis from $27.5 million in Q1 2016.
Exelixis (EXEL) Short term Debt (2010 - 2017) Analysis & Trends
Exelixis' Short term Debt history runs 8 years deep, the most recent figure standing at $113.3 million for Q1 2017.
- In Q1 2017, Short term Debt rose 312.18% year-over-year to $113.3 million; the TTM figure through Mar 2017 stood at $113.3 million (up 312.18% YoY), while the FY2016 annual figure was $109.1 million, changed N/A from the prior year.
- Short term Debt was $113.3 million for Q1 2017 at Exelixis, up from $109.1 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $113.3 million in Q1 2017 to a low of $450000.0 in Q3 2015.
- Historically, Short term Debt has averaged $45.7 million across 5 years, with a median of $27.5 million in 2016.
- The sharpest annual moves came in 2015 and 2016: Short term Debt plunged 99.53% in 2015, then soared 6425.56% in 2016.
- A 5-year view of Short term Debt shows it stood at $10.0 million in 2013, then jumped by 874.49% to $97.4 million in 2014, then tumbled by 99.54% to $450000.0 in 2015, then jumped by 24149.33% to $109.1 million in 2016, then grew by 3.87% to $113.3 million in 2017.
- The last three Short term Debt figures came in at $113.3 million (Q1 2017), $109.1 million (Q4 2016), and $29.4 million (Q3 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 113.35 Mn |
| Dec 30, 2016 | 109.12 Mn |
| Sep 30, 2016 | 29.37 Mn |
| Jun 30, 2016 | 27.50 Mn |
| Mar 31, 2016 | 27.50 Mn |
| Sep 30, 2015 | 450,000.00 |
| Mar 31, 2015 | 3.91 Mn |
| Dec 31, 2014 | 97.45 Mn |
| Sep 30, 2014 | 96.50 Mn |
| Jun 30, 2014 | 94.21 Mn |
| Dec 31, 2013 | 10.00 Mn |
| Sep 30, 2013 | 10.00 Mn |
| Jun 30, 2013 | 10.00 Mn |
| Mar 31, 2013 | 10.00 Mn |
| Dec 31, 2012 | 10.00 Mn |
| Sep 30, 2012 | 10.00 Mn |
| Jun 30, 2012 | 10.00 Mn |
| Mar 31, 2012 | 10.00 Mn |
| Sep 30, 2011 | 28.90 Mn |
| Jun 30, 2011 | 28.90 Mn |